Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sizes Up Rx Industry; Will Wall Street See Bulk As Strategic Asset?

Executive Summary

Pfizer is heading past the $50 bil. revenue level in 2004, but its biggest challenge may be convincing investors that its staggering size offers a competitive advantage
Advertisement

Related Content

Lipitor Scripts Rebounding, Pfizer Says; Cholesterol Category Still Has Life
Schering-Plough Faces Criminal Case; Off-Label Promotion May Be One Count
Cardinal Wants New Deal With Bristol; Inventory Practices Reduce Rx Growth
Iraq War Rally Helps Rx Stocks; Investors Adjust To Diminished Expectations?
Iraq War Rally Helps Rx Stocks; Investors Adjust To Diminished Expectations?
Rx Market Starts Slow In 2003; IMS Still Confident Of Double-Digit Growth
Advertisement
UsernamePublicRestriction

Register

PS042105

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel